Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression

American Journal of Pathology

Volumn 153, Issue 3, 1998, Pages 887-897

  Villuendas, Raquel ^a   Sánchez Beato, Margarita ^a   Martínez, Juan C ^a   Saez, Ana I ^a   Martinez Delgado, Beatriz ^b   García, Juan F ^a   Mateo, M Sol ^a   Sanchez Verde, L ^a   Benítez, Javier ^b   Martínez, Pedro ^a   Piris, Miguel A ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b Diaz University Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P16;

ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; FOLLICULAR LYMPHOMA; GENE LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; NONSENSE MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; TUMOR GROWTH;

EID: 0031655803     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65630-1     Document Type: Article

References (40)

1. Peter M, Herskowitz I: Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 1994, 79:181-184
2. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995, 9:1149-1163
3. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707
4. Hannon GJ, Beach D: p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994, 371:257-261
5. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D: Inhibition of ras-induced proliferation and cellular transformation by P16INK4. Science 1995, 267:249-252
6. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stocken E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440
7. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756
8. Siebert R, Willers CP, Schramm A, Fossa A, Dresen IM, Uppenkamp, M, Nowrousian MR, Seeber S, Opalka B: Homozygous loss of the MTS1/P16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines. Br J Haematol 1995, 91:350-354
9. Giani C, Finocchiaro G: Mutation rate in CDKN2 gene in malignant gliomas. Cancer Res 1994, 54:6338-6339
10. Fountain JW, Karayiorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaradhi S, Houghton AN, Lahti J, Housman DE, Dracopoli NC: Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992, 89:10557-10561
11. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet, 1994, 8:15-21
12. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-32
13. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995, 55:514-517
14. Ogawa S, Hangaishi A, Miyawak, S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, Shimazaki C, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Emi N, Yazaki Y, Ueda R, Hirai H: Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995, 86:1548-1556
15. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MA, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS: Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 1995, 85:893-901
16. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D: Frequency of homozygous deletion at p16/ CDKN2 in primary tumours. Nat Genet 1995, 11:210-212
17. Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, Hotta T: Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas. Blood 1995, 86:724-1731
18. Koduru PR, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD: Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. Blood 1995, 86:2900-2905
19. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995, 1:686-692
20. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 1995, 55:2995-2997
21. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K, Kurokawa M, Tanaka T, Mitani K, Yazaki Y, Hirai H: Homozygous loss of the cyclin-dependent kinasa 4-inhibitor (p16) gene in human leukemias. Blood 1994, 84:2431-2435
22. Aiello A, Delia D, Borrello MG, Biassoni D, Giardini R, Fontanella E, Pezzella F, Pulford K, Pierotti M, Della Porta G: Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry 1992, 13:502-509
23. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink, H-K, Pileri SA, Piris MA, Ralfkiaer, Warnke RA: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392
24. INK4A expression in human breast cancer. Am J Pathol 1996, 149:15-20
25. Geradts J, Kratzke RA, Niehans GA, Lincoln CE: Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995, 55:6006-6011
26. Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989, 5:874-879
27. Martinez-Delgado B, Fernandez-Piqueras J, Carca MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benítez J: Hypermethylation of 5′ CpG island of p16 is a frequent event in non Hodgkin's Lymphomas. Leukemia 1997, 11:425-428
28. Li M, Zhang ZF, Reuter V, Cordon-Cardo C. Chromosome 3 allelic losses, and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol 1996, 149:229-235
29. Tam SW, Shay JW, Pagano M: Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16lnk4. Cancer Res 1994, 54:5816-5820
30. Reed JA, Loganzo F Jr, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW, Albino AP: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 1995, 55:2713-2718
31. Nishikawa R, Furnari FB, Lin H, Arap W, Berger MS, Cavanee WK, Huang H-JS: Loss of p16INK4 expression is frequent in high-grade gliomas. Cancer Res 1995, 55:1941-1945
32. Kratzke RA, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J, Kaye FJ: Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995, 87:1870-1875
33. Montalban C, Castrilio JN, Abraira V, Serrano M, Bellas C, Piris MA, Carrion R, Cruz MA, Lara a JC, Menarguez J, Gomez-Marcos F, Rivas C: Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphomas: clinicopathological study and evaluation of the prognosis factor in 143 patients. Ann Oncol 1995, 6:355-362
34. Cayuela JM, Mandani A, Sanhes L, Stern MH, Sigaux F: Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 1996, 87: 2180-2186
35. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S, Hayashi Y: Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995, 86:1269-1275
36. Gombart AF, Morosetti R, Miller CW, Said JW, Koeffler HP: Deletions of the cyclin-dependent kinase inhibitor genes p16INK4A and p15INK4B in non-Hodgkin's lymphomas. Blood 1995, 86:1534-1539
37. Dreyling MH, Bohlander SK, Le Beau MM, Olopade OI: Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies. Blood 1995, 86:1931-1938
38. WAF1 genes are associated with aggressive variants of mantle cell lymphoma. Blood 1997, 89:272-280
39. INK4A characterize the major types of hematological malignancies. Cancer Res 1997, 57:837-841
40. Ng MHL, Chung YF, Lo KW, Wickham NWR, Lee JCK, Huang DP: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997, 89:2500-2506